NCT05152498Unknown早期 1 期
Forming a Comprehensive Treatment Plan for the Treatment of Hepatitis B Virus Related Hepatocellular Carcinoma With the Core Principles of Fuzheng Jiedu Huayu
Beijing Ditan Hospital1 个研究点 分布在 1 个国家目标入组 142 人开始时间: 2021年1月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 早期 1 期
- 发起方
- 入组人数
- 142
- 试验地点
- 1
- 主要终点
- Time to Progression
研究概览
简要总结
The treatment of HBV related hepatocellular carcinoma has always been a worldwide problem. The aim of this study is to alleviate the progression of hepatitis B related hepatocellular carcinoma by the Chinese medicine "Fu Zheng Jie Du Hua Yu" Principle.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Meet the criteria of hepatocellular carcinoma
- •Ages Eligible for Study: ≤75 years old;
- •Informed consent from the patient.
排除标准
- •Serious problem of heart, lung, or kidney with severe dysfunction;
- •Pregnant or child breast feeding women;
- •Mental or cognitive disorders;
- •Participating in other drug trials;
- •Who are allergic to the study drug
研究组 & 干预措施
Fu Zheng Jie Du Hua Yu therapy
Experimental
干预措施: Fu Zheng Jie Du Hua Yu therapy (Drug)
Routine medical care
Experimental
干预措施: Fu Zheng Jie Du Hua Yu therapy (Drug)
结局指标
主要结局
Time to Progression
时间窗: 1 year
次要结局
- progression-free survival(1 year)
- overall survival(1 year)
- complete response(1 year)
研究者
Zhiyun Yang
Archiater, Professor
Beijing Ditan Hospital
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated CirrhosisHepatitis B, ChronicCompensated CirrhosisHepatocellular CarcinomaNCT04160897Qing XIe4,000
已完成
2 期
GH, IGF-I and Somatostatin Analogues in Hepatocellular CarcinomaAdvanced Hepatocellular CarcinomaNCT00495846Federico II University25
已完成
不适用
A New Conception About Individualized Treatment Allocation for HCCTransarterial ChemoembolizationResectionHCCNCT06008548Tang-Du Hospital4,991
已完成
1 期
A Basic-clinical Translational Research in Hepatitis B Virus (HBV)-Specific Antigen Peptides and HepG2 Cell Lysate Co-activated Dendritic Cells Combined With Transarterial Chemoembolization (TACE) in HBV-related HCC Treatment (BTRHBVAPHCLCDCCTCHBVHCCT)Hepatocellular CarcinomaNCT03086564Yuehua Huang70
Unknown
2 期
"Cocktail" Therapy for Hepatitis B Related Hepatocellular CarcinomaHepatocellular CarcinomaNCT04317248Yuehua Huang600